Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
NCT ID: NCT06041516
Last Updated: 2025-07-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
70 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-06-17
Study Completion Date
2029-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of relapse and a low chance of survival. Better treatments are needed.
Objective:
To test a new drug, ADCT-701, in people with NENs.
Eligibility:
Adults aged 18 and older with NENs.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and tests of heart functioning. Their ability to perform normal daily activities will be tested. A biopsy may be needed: A sample of tissue will be removed from the tumor.
ADCT-701 is given through a tube attached to a needle inserted into a vein in the arm. Participants will receive the drug treatment on the first day of 21-day treatment cycles. They will visit the clinic a total of 10 times during the first two cycles. After that, they will visit the clinic 2 times during each cycle. Imaging scans, blood draws, heart function tests, and other tests will be repeated during study visits. Each visit will last up to 8 hours.
Participants may continue receiving treatment with the study drug for up to 2 years.
After treatment ends, participants will have follow-up clinic visits 4 times in 4 months. They will have a physical exam, with heart and blood tests, at each visit. After that, they will have follow-up clinic visits every 9 weeks; these visits will include imaging scans.
Follow-up visits will continue for up to 5 years after treatment began....
Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of relapse and a low chance of survival. Better treatments are needed.
Objective:
To test a new drug, ADCT-701, in people with NENs.
Eligibility:
Adults aged 18 and older with NENs.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and tests of heart functioning. Their ability to perform normal daily activities will be tested. A biopsy may be needed: A sample of tissue will be removed from the tumor.
ADCT-701 is given through a tube attached to a needle inserted into a vein in the arm. Participants will receive the drug treatment on the first day of 21-day treatment cycles. They will visit the clinic a total of 10 times during the first two cycles. After that, they will visit the clinic 2 times during each cycle. Imaging scans, blood draws, heart function tests, and other tests will be repeated during study visits. Each visit will last up to 8 hours.
Participants may continue receiving treatment with the study drug for up to 2 years.
After treatment ends, participants will have follow-up clinic visits 4 times in 4 months. They will have a physical exam, with heart and blood tests, at each visit. After that, they will have follow-up clinic visits every 9 weeks; these visits will include imaging scans.
Follow-up visits will continue for up to 5 years after treatment began....
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT05098210
Anatomic Stage IV Breast Cancer AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Locally Advanced Cutaneous Melanoma
+22 more
RECRUITING
PHASE1
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
NCT05964361
Esophageal Cancer
Pancreas Cancer
Ovarian Cancer
+1 more
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
Acinar Cell Carcinoma
Adenoid Cystic Carcinoma
Adrenal Cortical Carcinoma
+91 more
ACTIVE_NOT_RECRUITING
PHASE2
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
NCT04111172
Pancreatic Ductal Adenocarcinoma
Colorectal Adenocarcinoma
Gastric Adenocarcinoma
+35 more
ACTIVE_NOT_RECRUITING
PHASE2
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
NCT04847466
Gastroesophageal Junction (GEJ) Cancers
Advanced HNSCC
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
-Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring in areas such as the gastrointestinal tract, islets of the pancreas, lung, adrenal gland, and other areas of
the body.
* Poorly differentiated neuroendocrine carcinomas are all high-grade carcinomas that resemble small-cell lung cancer (SCLC). Poorly differentiated NECs are also treated with platinum-based regimens in accordance with small cell carcinoma guidelines and have a high risk of relapse as well as a poor response to further systemic therapies.
* Adrenocortical carcinoma (ACC) is a rare malignancy with an average survival from the time of diagnosis of 14.5 months. In advanced diseases, chemotherapy options have limited benefits. To date, no "targeted therapy" has been shown to have significant efficacy in this disease.
* Pre-clinical studies have shown that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in multiple neuroendocrine neoplasms such as ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.
* ADCT-701 a humanized antibody directed against DLK1 effectively suppresses tumor growth and improves survival in multiple cancer models which express DLK1.
Objective:
-To determine the maximum tolerated dose (MTD) of ADCT-701 in participants with neuroendocrine neoplasms or malignant adrenocortical carcinoma
Eligibility:
* Histologically or cytologically confirmed neuroendocrine neoplasms or malignant ACC.
* Age \>= 18 years.
* Evaluable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
* Adequate organ and bone marrow function.
* Eastern Cooperative Oncology Group (ECOG) \<= 2.
Design:
* This is a First in Human phase I dose escalation study of ADCT-701-single agent in participants with NENs.
* Participants will be enrolled in a dose-finding trial. A 3+3 design with up to ten dose levels of ADCT-701 will be evaluated in this trial. The study drug dose will be escalated unless the occurrence of dose-limiting toxicities limits further escalation or until the maximum tolerated dose level is reached or an optimal dose is determined.
* Up to 70 evaluable patients will be enrolled over a maximum of 10 dose levels.
-Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring in areas such as the gastrointestinal tract, islets of the pancreas, lung, adrenal gland, and other areas of
the body.
* Poorly differentiated neuroendocrine carcinomas are all high-grade carcinomas that resemble small-cell lung cancer (SCLC). Poorly differentiated NECs are also treated with platinum-based regimens in accordance with small cell carcinoma guidelines and have a high risk of relapse as well as a poor response to further systemic therapies.
* Adrenocortical carcinoma (ACC) is a rare malignancy with an average survival from the time of diagnosis of 14.5 months. In advanced diseases, chemotherapy options have limited benefits. To date, no "targeted therapy" has been shown to have significant efficacy in this disease.
* Pre-clinical studies have shown that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in multiple neuroendocrine neoplasms such as ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.
* ADCT-701 a humanized antibody directed against DLK1 effectively suppresses tumor growth and improves survival in multiple cancer models which express DLK1.
Objective:
-To determine the maximum tolerated dose (MTD) of ADCT-701 in participants with neuroendocrine neoplasms or malignant adrenocortical carcinoma
Eligibility:
* Histologically or cytologically confirmed neuroendocrine neoplasms or malignant ACC.
* Age \>= 18 years.
* Evaluable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
* Adequate organ and bone marrow function.
* Eastern Cooperative Oncology Group (ECOG) \<= 2.
Design:
* This is a First in Human phase I dose escalation study of ADCT-701-single agent in participants with NENs.
* Participants will be enrolled in a dose-finding trial. A 3+3 design with up to ten dose levels of ADCT-701 will be evaluated in this trial. The study drug dose will be escalated unless the occurrence of dose-limiting toxicities limits further escalation or until the maximum tolerated dose level is reached or an optimal dose is determined.
* Up to 70 evaluable patients will be enrolled over a maximum of 10 dose levels.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neuroendocrine Carcinomas
Neuroendocrine Tumors
Carcinoma, Neuroendocrine
Carcinoma, Adrenocortical
Carcinoma, Adrenal Cortical
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1/Arm1
ADCT-701 given as an IV infusion
Group Type
EXPERIMENTAL
ADCT-701
Intervention Type
DRUG
ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADCT-701
ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have histologically or cytologically confirmed neuroendocrine neoplasms or malignant adrenocortical carcinoma (ACC).
* Locally advanced or metastatic disease (as confirmed by a radiological evaluation).
* Participants must have measurable disease per RECIST 1.1.
* Participants must have received prior standard of care treatment and be refractory to or intolerant to standard of care therapy(s).
* Age \>= 18 years.
* ECOG performance status \<= 2.
* Adequate hematologic function as follows:
* Leukocytes \>= 3,000/microliter
* Absolute neutrophil count (ANC) \>= 1,200/microliter (off-growth factors for 72 hours prior to treatment initiation)
* Hemoglobin (Hgb) \>= 9 g/dL with no blood transfusion within 2 weeks prior to treatment initiation
* Platelets \>= 100,000/microliter with no platelet transfusion within 1 week.
* Adequate renal and hepatic function as follows:
* Creatinine clearance (CrCl) \>= 50 mL/min/1.73 m\^2 (calculated CrCl (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or calculated eGFR provided by a laboratory))
* Total bilirubin \<= 1.5 x ULN OR in participants with known or suspected Gilbert's syndrome, total bilirubin \<= 3.0 x ULN
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<= 2.5 x ULN, (unless liver metastases are present, then values must be \<= 5 x ULN).
* Participants serologically positive for hepatitis C virus (HCV) must have an undetectable HCV viral load.
* Participants serologically positive for Hepatitis B (HBV) core antibody or surface antigen must be on adequate anti-viral therapy and Hepatitis B Viral deoxyribonucleic acid (DNA) load must be \<2000 IU/mL.
* Participants serologically positive for human immunodeficiency virus (HIV) must be on stable antiretroviral therapy for at least 4 weeks before treatment initiation, have no reported opportunistic infections or Castleman s disease within 12 months prior to treatment initiation, have a viral load that is undetectable by quantitative polymerase chain reaction (PCR) and CD4 count \>= 200 cells per cubic millimeter.
* Participants with brain metastasis are eligible if at least 4 weeks status post radiotherapy or surgery before treatment initiation with no evidence of progression or associated symptoms.
* Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization) for the duration of the study treatment and up to 9.5 months after the last dose of the ADCT-701 (restriction period).
Individuals who can father children must agree to use an effective method of contraception (barrier, surgical sterilization) at study entry and up to 6.5 months after the last dose of the ADCT-701.
* Nursing participants must be willing to discontinue nursing from study treatment initiation through 6.5 months after study treatment discontinuation.
* Participants must be able to understand and be willing to sign a written informed consent document.
* Locally advanced or metastatic disease (as confirmed by a radiological evaluation).
* Participants must have measurable disease per RECIST 1.1.
* Participants must have received prior standard of care treatment and be refractory to or intolerant to standard of care therapy(s).
* Age \>= 18 years.
* ECOG performance status \<= 2.
* Adequate hematologic function as follows:
* Leukocytes \>= 3,000/microliter
* Absolute neutrophil count (ANC) \>= 1,200/microliter (off-growth factors for 72 hours prior to treatment initiation)
* Hemoglobin (Hgb) \>= 9 g/dL with no blood transfusion within 2 weeks prior to treatment initiation
* Platelets \>= 100,000/microliter with no platelet transfusion within 1 week.
* Adequate renal and hepatic function as follows:
* Creatinine clearance (CrCl) \>= 50 mL/min/1.73 m\^2 (calculated CrCl (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or calculated eGFR provided by a laboratory))
* Total bilirubin \<= 1.5 x ULN OR in participants with known or suspected Gilbert's syndrome, total bilirubin \<= 3.0 x ULN
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<= 2.5 x ULN, (unless liver metastases are present, then values must be \<= 5 x ULN).
* Participants serologically positive for hepatitis C virus (HCV) must have an undetectable HCV viral load.
* Participants serologically positive for Hepatitis B (HBV) core antibody or surface antigen must be on adequate anti-viral therapy and Hepatitis B Viral deoxyribonucleic acid (DNA) load must be \<2000 IU/mL.
* Participants serologically positive for human immunodeficiency virus (HIV) must be on stable antiretroviral therapy for at least 4 weeks before treatment initiation, have no reported opportunistic infections or Castleman s disease within 12 months prior to treatment initiation, have a viral load that is undetectable by quantitative polymerase chain reaction (PCR) and CD4 count \>= 200 cells per cubic millimeter.
* Participants with brain metastasis are eligible if at least 4 weeks status post radiotherapy or surgery before treatment initiation with no evidence of progression or associated symptoms.
* Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization) for the duration of the study treatment and up to 9.5 months after the last dose of the ADCT-701 (restriction period).
Individuals who can father children must agree to use an effective method of contraception (barrier, surgical sterilization) at study entry and up to 6.5 months after the last dose of the ADCT-701.
* Nursing participants must be willing to discontinue nursing from study treatment initiation through 6.5 months after study treatment discontinuation.
* Participants must be able to understand and be willing to sign a written informed consent document.
Exclusion Criteria
* Major surgery, prior treatment with chemotherapy, hormonal therapy, immunotherapy, treatment with an investigational agent, and/or radiation therapy within 4 weeks or 5 halflives, whichever is shorter, prior to treatment initiation.
* Participants taking any herbal supplements within 14 days prior to treatment initiation.
* Participants who have wound dehiscence from prior surgeries.
* Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or any serosal effusion that is either requires drainage or is associated with shortness of breath) at screening.
* Active infection requiring systemic antibiotic therapy at screening.
* Active bleeding diathesis or therapeutic anticoagulation with an oral vitamin K antagonist with target international normalized ratio (INR) \> 2 at screening.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug.
* An active autoimmune disease. Note: Participants with type 1 diabetes, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease, adrenal insufficiency on systemic oral corticosteroid therapy (\<= the equivalent of prednisone 10 mg/day), or other mild autoimmune disorders (Type 1 diabetes, eczema, vitiligo, alopecia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, adrenal insufficiency due to Addison s disease, hypothyroidisms due to Hashimoto s thyroiditis, hyperthyroidisms due to Graves disease, Sjogren s syndrome, celiac disease, pernicious anemia) not requiring immunosuppressive treatment are eligible.
* Congenital long QT syndrome, or a corrected QTcF interval of \>=480 ms, at screening (unless secondary to the pacemaker or bundle branch block).
* Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that does not require current anticancer treatment per standard of care.
* Live vaccine administration within 30 days prior to treatment initiation.
* Pregnant individuals (confirmed by Beta-Human Chorionic Gonadotropin \[Beta-HCG\] serum or urine pregnancy test) performed at screening.
* Uncontrolled intercurrent illness that would limit compliance with study requirements.
* Participants taking any herbal supplements within 14 days prior to treatment initiation.
* Participants who have wound dehiscence from prior surgeries.
* Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or any serosal effusion that is either requires drainage or is associated with shortness of breath) at screening.
* Active infection requiring systemic antibiotic therapy at screening.
* Active bleeding diathesis or therapeutic anticoagulation with an oral vitamin K antagonist with target international normalized ratio (INR) \> 2 at screening.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug.
* An active autoimmune disease. Note: Participants with type 1 diabetes, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease, adrenal insufficiency on systemic oral corticosteroid therapy (\<= the equivalent of prednisone 10 mg/day), or other mild autoimmune disorders (Type 1 diabetes, eczema, vitiligo, alopecia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, adrenal insufficiency due to Addison s disease, hypothyroidisms due to Hashimoto s thyroiditis, hyperthyroidisms due to Graves disease, Sjogren s syndrome, celiac disease, pernicious anemia) not requiring immunosuppressive treatment are eligible.
* Congenital long QT syndrome, or a corrected QTcF interval of \>=480 ms, at screening (unless secondary to the pacemaker or bundle branch block).
* Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that does not require current anticancer treatment per standard of care.
* Live vaccine administration within 30 days prior to treatment initiation.
* Pregnant individuals (confirmed by Beta-Human Chorionic Gonadotropin \[Beta-HCG\] serum or urine pregnancy test) performed at screening.
* Uncontrolled intercurrent illness that would limit compliance with study requirements.
Minimum Eligible Age
18 Years
Maximum Eligible Age
120 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaydira Del Rivero, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Taniyama D, Patel M, Aber E, Contreras CF, Kaplan RN, Kiseljak-Vassiliades K, Wierman ME, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Del Rivero J, Roper N. Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. Nat Commun. 2025 Jul 1;16(1):5511. doi: 10.1038/s41467-025-60649-w.
Reference Type
DERIVED
Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Patel M, Aber E, Contreras-Burrola C, Kaplan R, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Rivero JD, Roper N. Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. bioRxiv [Preprint]. 2024 Oct 11:2024.10.09.617077. doi: 10.1101/2024.10.09.617077.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_001547-C.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
001547-C
Identifier Type: -
Identifier Source: secondary_id
10001547
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors
NCT06614140
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
NCT03480152
TERMINATED
PHASE1/PHASE2
QUILT-3.088: NANT Pancreatic Cancer Vaccine
NCT03563144
WITHDRAWN
PHASE2
Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer
NCT00874588
COMPLETED
PHASE1
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382
RECRUITING
PHASE2
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
NCT04187404
TERMINATED
PHASE1/PHASE2
A Study of Personalized Neoantigen Cancer Vaccines
NCT03794128
COMPLETED
Personalized Neoantigen Peptide Vaccines for Solid Tumors
NCT07002203
RECRUITING
PHASE1/PHASE2
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
NCT00019006
COMPLETED
PHASE1
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
NCT03300843
TERMINATED
PHASE2
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
NCT02720484
TERMINATED
PHASE2
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
NCT03074513
ACTIVE_NOT_RECRUITING
PHASE2
An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment
NCT04087252
UNKNOWN
PHASE1
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
NCT00003102
COMPLETED
PHASE1/PHASE2
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825
RECRUITING
PHASE1
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
NCT00052403
WITHDRAWN
PHASE1
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
NCT06631079
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
NCT02832167
COMPLETED
PHASE2
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
NCT02598960
COMPLETED
PHASE1/PHASE2
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
NCT03384316
COMPLETED
PHASE1
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
NCT00031564
COMPLETED
PHASE2
Agnostic Therapy in Rare Solid Tumors
NCT06638931
ACTIVE_NOT_RECRUITING
PHASE2
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
NCT06597721
RECRUITING
PHASE1
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
NCT07262489
NOT_YET_RECRUITING
PHASE2